TickerTalks
Browse all tickers →
TickerTalks›$RVTY
RVRVTY

Revvity, Inc.

$RVTY·$12B·Medical - Diagnostics & Research·Healthcare
$110.52+3.8%YTD+13.7%1Y+17.3%
Mentions · last 7 days
2026-07-14: 0 posts2026-07-15: 2 posts2026-07-16: 1 posts2026-07-17: 2 posts2026-07-18: 0 posts2026-07-19: 0 posts2026-07-20: 0 posts5
Price updated 3m ago·X counts updated 23h ago
RVRVTY
$RVTYRevvity, Inc.
$110.52+3.83%5 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $RVTY, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersEvent coming upAI verdict · as of 2026-07-21

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Revvity up 10% YTD — life-sciences and diagnostics leader with 7% growth reports Q2 August 4.

Revvity Inc. (formerly PerkinElmer's Diagnostics-plus-Life-Sciences) is the life-sciences instruments and diagnostics specialist (reproductive health, newborn screening, life-sciences tools) — a name that has quietly compounded on the specific diagnostics-plus-life-sciences thesis.

  • Growth is real: Q1 2026 revenue of $711M was up 7.0% YoY — the pattern showing life-sciences instruments plus diagnostics demand is compounding at mid-single digits.
  • At $106.44 and +10% YTD, the tape reflects the specific diagnostics-plus-life-sciences rerating capture — the August 4 Q2 print is the specific test.
  • The FY26 EPS $1.23 Q2 consensus supports the full-year trajectory — needed for the specific diagnostics-plus-life-sciences cycle persistence.
  • Revvity's dual-vertical positioning creates specific structural setup that requires specific commercial disclosure cadence.

Path forward is the August 4 Q2 print — need FY26 EPS $1.23 Q2 consensus holding plus explicit diagnostics-plus-life-sciences segment revenue mix commentary. What extends the move: a beat-plus-raise plus explicit reproductive-health-plus-newborn-screening acceleration; what invalidates: any life-sciences instruments cycle softening or a walked-back FY26 EPS trajectory.

What to watch: August 4 Q2 print — FY26 EPS $1.23 Q2 holding and diagnostics-plus-life-sciences segment revenue mix commentary matter most. A beat-plus-raise plus explicit reproductive-health-plus-newborn-screening acceleration is the specific extension catalyst.

On the calendar: 2026-08-04 — Q2 earnings

sentiment missing

Read the AI verdict + X sentiment for $RVTY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $RVTY.

Medical - Diagnostics & Research · Healthcare

No material change from last week — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials.

What this means for $RVTY

Partial — Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed i; partial earnings exposure to medical - diagnostics & research demand dynamics through its product portfolio.

Industry benchmark

14-name peer basket
+31.1%YTD
+64.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
52.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
2.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
12.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
3.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
51.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$1.06$1.02+3.9%
Q4 2025Feb 2, 2026$1.70$1.57+8.3%
Q3 2025Oct 27, 2025$1.18$1.14+3.5%
Q2 2025Jul 28, 2025$1.18$1.14+3.5%
Next earningsTue, Aug 4·consensus EPS $1.23

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$711.1M+7.0%54.5%10.7%$0.36$95.3M
Q4 FY25$772.1M+5.9%43.8%14.5%$0.87$163.1M
Q3 FY25$698.9M+2.2%53.6%11.7%$0.40$120.1M
Q2 FY25$720.3M+4.1%54.5%12.6%$0.47$115.5M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.8B$2.8B – $2.8B$5.24$5.23 – $5.259
FY27$3.0B$2.9B – $3.1B$5.81$5.80 – $5.839
FY28$3.2B$3.1B – $3.2B$6.45$6.35 – $6.567
FY29$3.3B$3.3B – $3.4B$6.96$6.85 – $7.256
FY30$3.5B$3.4B – $3.6B$7.51$7.39 – $7.823

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.68%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 102.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.095-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellApr 20Anita GonzalesPresident80 sh$7KSellFeb 24Miriame VictorPlease See Remarks1.9K sh$181KSellFeb 23Michelle Mcmurry-heathDirector600 sh$58KSellFeb 5Prahlad R. SinghPlease See Remarks25.5K sh$2.6M
+ 24 other (13 awards · 9 inkinds · 2 exempts) in window

See when $RVTY insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KCharter amendmentMay 18-K — Item 5.03: Charter amendment · Item 5.07: Shareholder vote
+ 15 other (4 13Gs · 2 proxys · 1 25-NSE · 1 11-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosurebusinesswire.com·2d agoRevvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day Onebusinesswire.com·2d agoRevvity to Hold Earnings Call on Tuesday, August 4, 2026businesswire.com·14d agoRevvity Expands Signals AI With Anthropic Claude Integrationzacks.com·19d agoRevvity Expands Signals AI Ecosystem Through Anthropic Claude Integrationbusinesswire.com·21d ago

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMO$DHR$PSNL$IQV$A$TWST$ILMN$STIM
Voices on X · last 7 days

No standout posts about $RVTY on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport